Shenluo Medical

About Shenluo Medical

Established in December 2018 in Hangzhou, China, Shenluo Medical Technology Co., Ltd. (also known as Seeneuro Medical) operates within the active implantable medical device sector, specializing in neuromodulation and brain-computer interface technologies. The company was founded by Wang Shoudong, who leads a core team noted for its extensive experience in the development and production of implantable medical devices. This collective expertise forms the foundation of the company's research and development-centric strategy.

Shenluo Medical's business model is focused on the in-house development and manufacturing of advanced medical devices for a business-to-business market, serving hospitals and other medical institutions. Revenue is generated through the sale of these specialized therapeutic systems. The firm's primary objective is to provide effective treatment options for patients suffering from chronic and refractory diseases. Since its inception, the company has secured significant capital through multiple funding rounds, including a Series B financing of nearly CNY 100 million in October 2022, led by SDIC Unity Capital with participation from existing investor BioTrack Capital. A subsequent B+ round in April 2024, led by OrbiMed, raised several hundred million CNY to fund new product development, clinical trials, and commercial expansion.

The company's product pipeline is centered on providing solutions for chronic pain management with plans to address other neurological and autonomic disorders. Its core products include a Spinal Cord Stimulation (SCS) system and a short-term implantable Peripheral Nerve Stimulation (PNS) system. The SCS device, which has completed initial human clinical trials, is designed for patients with chronic intractable pain. Shenluo Medical has developed three core technology platforms: a short-term implantable platform, a rechargeable Implantable Pulse Generator (IPG) platform, and a wireless power transfer platform, which are protected by a portfolio of over 100 patents and software copyrights. Future expansion of its product lines targets conditions such as epilepsy, heart failure, overactive bladder, and sleep apnea.